Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease ; volume:11 ; number:1 ; day:25 ; month:5 ; year:2011 ; pages:1-8 ; date:12.2011
BMC neurology ; 11, Heft 1 (25.5.2011), 1-8, 12.2011
- Urheber
-
Farlow, Martin
- Beteiligte Personen und Organisationen
-
Veloso, Felix
Moline, Margaret
Yardley, Jane
Brand-Schieber, Elimor
Bibbiani, Francesco
Zou, Heng
Hsu, Timothy
Satlin, Andrew
SpringerLink (Online service)
- DOI
-
10.1186/1471-2377-11-57
- URN
-
urn:nbn:de:1111-2016030329862
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Farlow, Martin
- Veloso, Felix
- Moline, Margaret
- Yardley, Jane
- Brand-Schieber, Elimor
- Bibbiani, Francesco
- Zou, Heng
- Hsu, Timothy
- Satlin, Andrew
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy
Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
Correction to: Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy
Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
Correction to: Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
Nutritional management for Alzheimer’s disease in all stages: mild, moderate, and severe
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy
Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
Correction to: Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy